127 related articles for article (PubMed ID: 34954155)
21. Stimulation of DDX3 expression by ginsenoside Rg3 through the Akt/p53 pathway activates the innate immune response via TBK1/IKKε/IRF3 signalling.
Choi YJ; Kang LJ; Lee SG
Curr Med Chem; 2014; 21(8):1050-60. PubMed ID: 24180280
[TBL] [Abstract][Full Text] [Related]
22. TRIM65 negatively regulates p53 through ubiquitination.
Li Y; Ma C; Zhou T; Liu Y; Sun L; Yu Z
Biochem Biophys Res Commun; 2016 Apr; 473(1):278-282. PubMed ID: 27012201
[TBL] [Abstract][Full Text] [Related]
23. Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer.
Bol GM; Raman V; van der Groep P; Vermeulen JF; Patel AH; van der Wall E; van Diest PJ
PLoS One; 2013; 8(5):e63548. PubMed ID: 23696831
[TBL] [Abstract][Full Text] [Related]
24. Analysis of defective protein ubiquitylation associated to adriamycin resistant cells.
Lang V; Aillet F; Xolalpa W; Serna S; Ceccato L; Lopez-Reyes RG; Lopez-Mato MP; Januchowski R; Reichardt NC; Rodriguez MS
Cell Cycle; 2017; 16(24):2337-2344. PubMed ID: 29099265
[TBL] [Abstract][Full Text] [Related]
25. The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in
Wu DW; Lin PL; Wang L; Huang CC; Lee H
Theranostics; 2017; 7(5):1114-1132. PubMed ID: 28435452
[TBL] [Abstract][Full Text] [Related]
26. BCAS3 exhibits oncogenic properties by promoting CRL4A-mediated ubiquitination of p53 in breast cancer.
Zhou Z; Qiu R; Liu W; Yang T; Li G; Huang W; Teng X; Yang Y; Yu H; Yang Y; Wang Y
Cell Prolif; 2021 Aug; 54(8):e13088. PubMed ID: 34240781
[TBL] [Abstract][Full Text] [Related]
27. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
28. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
29. Regulation of p21 expression for anti-apoptotic activity of DDX3 against sanguinarine-induced cell death on intrinsic pathway.
Nguyen CN; Nguyen KVA; Eom S; Choi YJ; Kang LJ; Lee J; Kim C; Lee S; Lee SG; Lee JH
Phytomedicine; 2019 Dec; 65():153096. PubMed ID: 31568920
[TBL] [Abstract][Full Text] [Related]
30. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway.
Chen HH; Yu HI; Cho WC; Tarn WY
Oncogene; 2015 May; 34(21):2790-800. PubMed ID: 25043297
[TBL] [Abstract][Full Text] [Related]
31. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
32. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.
Park EY; Chang E; Lee EJ; Lee HW; Kang HG; Chun KH; Woo YM; Kong HK; Ko JY; Suzuki H; Song E; Park JH
Cancer Res; 2014 Dec; 74(24):7573-82. PubMed ID: 25368020
[TBL] [Abstract][Full Text] [Related]
33. DDX3, a potential target for cancer treatment.
Bol GM; Xie M; Raman V
Mol Cancer; 2015 Nov; 14():188. PubMed ID: 26541825
[TBL] [Abstract][Full Text] [Related]
34. Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment.
Heerma van Voss MR; Vesuna F; Bol GM; Afzal J; Tantravedi S; Bergman Y; Kammers K; Lehar M; Malek R; Ballew M; Ter Hoeve N; Abou D; Thorek D; Berlinicke C; Yazdankhah M; Sinha D; Le A; Abrahams R; Tran PT; van Diest PJ; Raman V
Oncogene; 2018 Jan; 37(1):63-74. PubMed ID: 28869602
[TBL] [Abstract][Full Text] [Related]
35. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.
Lv K; Liu L; Wang L; Yu J; Liu X; Cheng Y; Dong M; Teng R; Wu L; Fu P; Deng W; Hu W; Teng L
PLoS One; 2012; 7(7):e40008. PubMed ID: 22808086
[TBL] [Abstract][Full Text] [Related]
36. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A; González I; Menendez S; Arpí O; Corominas JM; Servitja S; Tusquets I; Chamizo C; Rincón R; Espinosa L; Bigas A; Eroles P; Furriol J; Lluch A; Rovira A; Albanell J; Rojo F
Oncotarget; 2014 Jan; 5(1):196-210. PubMed ID: 24344116
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.
Wang Y; Zhou P; Li P; Yang F; Gao XQ
Bioengineered; 2020 Dec; 11(1):536-546. PubMed ID: 32345117
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
39. Negative regulation of the p300-p53 interplay by DDX24.
Shi D; Dai C; Qin J; Gu W
Oncogene; 2016 Jan; 35(4):528-36. PubMed ID: 25867071
[TBL] [Abstract][Full Text] [Related]
40. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.
Han B; Huang J; Han Y; Hao J; Wu X; Song H; Chen X; Shen Q; Dong X; Pang H; Cai L
Int J Biol Macromol; 2019 Mar; 125():544-556. PubMed ID: 30537505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
